#1 Clinical Trials Search in Europe

Aluminium Oxide

Clinical trials investigating Aluminium Oxide are looking at treatment strategies for people with heartburn, reflux, and functional dyspepsia. The studies focus on whether antacid or antireflux approaches can support better symptom control and treatment decisions in patients who have been using proton pump inhibitors long term.

Table of Contents

Trial overview

The clinical trial data for Aluminium Oxide describe one completed interventional study called the Primary carE PPi dEprescRibing (PEPPER) trial.[1] It studied treatment strategies for people with heartburn, functional dyspepsia, and reflux.[1]

Who was studied

The trial focused on patients who were using proton pump inhibitors, or PPIs, for a long time without a clear reason for long-term use.[1] This means the study was aimed at people where the care team wanted to check whether the medicine could be reduced or replaced in a planned way.[1]

The conditions listed in the trial were heartburn, functional dyspepsia, and reflux.[1] These are common upper stomach or chest symptoms that can affect daily comfort and eating habits.[1]

What was compared in the study

The study compared three deprescribing strategies, which means three ways of reducing or stopping a medicine in a planned manner.[1] One approach was on-demand PPI use, where patients would use the medicine only when needed.[1]

The second approach replaced PPI therapy with an alginate formulation.[1] The trial records list several commercial products used in this group, including Maalox Antacid® and Gaviscon Antizuur – Antireflux Unidose.[1]

The third approach was the standard method of gradually lowering the PPI dose through fixed intermittent intake.[1] The study compared these approaches to see which one worked best for patients who did not clearly need long-term PPI treatment.[1]

Main endpoint and how success was measured

The main endpoint was the percentage of randomized patients who achieved a successful therapeutic outcome by the end of follow-up.[1] Randomized patients are people assigned by chance to one of the study groups, so the groups can be compared fairly.[1]

Success was based on three patient-reported points: use of PPI, treatment satisfaction, and willingness to continue with the treatment.[1] Patient-reported means the information came directly from what the patient said or reported, not only from lab tests or scans.[1]

Trial design and phase

This was an interventional study, which means the researchers assigned treatment strategies rather than only observing what happened naturally.[1] The trial was conducted as Phase 3, and it enrolled 745 participants.[1]

The study was completed, so the trial record shows that the planned comparison was finished.[1] The brief summary also states that the researchers expected the new deprescribing strategies, on-demand use and alginate replacement, to perform better than the standard gradual reduction approach.[1]

What the study aimed to show

The purpose of the trial was to find the best way to deprescribe PPIs in people who were taking them chronically without a firm long-term indication.[1] In simple terms, the researchers wanted to know whether a planned switch or reduction could work better than the usual step-down method.[1]

The study also tested whether one of the new strategies, on-demand PPI use, would be at least as good as the alginate replacement strategy.[1] This kind of comparison helps researchers choose the most practical option for future care decisions.[1]

Trial ID Phase Condition studied Status Enrollment
NCT05629143 Phase 3 Heartburn, functional dyspepsia, reflux Completed 745

FAQ

  • What are clinical trials studying Aluminium Oxide trying to find out? They are studying whether different treatment approaches can help people with heartburn, reflux, and functional dyspepsia. The main goal is to see which strategy leads to better patient-reported success.
  • Who can take part in these trials? The trial data describe patients who are chronically using proton pump inhibitors without a clear long-term reason. These are adults with symptoms such as heartburn, reflux, or functional dyspepsia.
  • What phase is the Aluminium Oxide trial? The trial is in Phase 3. This means it is testing the treatment strategy in a larger group of people to compare how well the approaches work.
  • What treatments are being compared in the study? The study compares on-demand proton pump inhibitor use, replacement with an alginate formulation, and gradual dose reduction with fixed intermittent intake. The goal is to find the best deprescribing strategy.
  • What result is the trial measuring? The main result is the percentage of patients with a successful therapeutic outcome at the end of follow-up. This is based on patient reports about proton pump inhibitor use, treatment satisfaction, and willingness to continue treatment.

Ongoing Clinical Trials on Aluminium Oxide

  • Study on Reducing Proton Pump Inhibitor Use in Patients with Heartburn, Reflux, or Dyspepsia: Comparing On-Demand Use, Alginate Therapy, and Gradual Dose Reduction

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Heartburn: A burning feeling in the chest or upper stomach area, often linked to acid coming up from the stomach.
  • Reflux: When stomach contents move back upward into the esophagus, which can cause burning or discomfort.
  • Functional dyspepsia: Upper stomach discomfort or pain without a clear structural cause found in testing.
  • Proton pump inhibitor (PPI): A medicine often used to reduce stomach acid. In this trial, the researchers are looking at ways to reduce or stop long-term use.
  • Deprescribing: A planned and careful reduction or stopping of a medicine that may no longer be needed.
  • On-demand use: Taking a medicine only when symptoms happen, instead of on a fixed daily schedule.
  • Alginate formulation: A treatment approach used in the trial as a replacement strategy for PPI therapy.
  • Gradual dose decrease: Lowering the medicine dose step by step over time instead of stopping all at once.
  • Randomized patients: People assigned by chance to different treatment groups so the results can be compared fairly.
  • Therapeutic outcome: The overall treatment result, based here on patient use of medicine, satisfaction, and willingness to continue.

References